Sengkang general hospital, Hospital in Singapore

VEITH 2022 witnessed a surge of supporting clinical data for Sirolimus Coated Balloon in the treatment of Below-the-Knee (BTK) disease. hosted a lunch symposium titled 'Sirolimus Coated Balloon in PAD Treatment: Choice of The Future' which explored the utility of Sirolimus Coated Balloon treatment in PAD. The session was chaired by Prof. Sahil Parikh, co-moderated by Prof. Edward Choke and Prof. Aloke Finn with interesting presentations by Prof. Ulf Teichgraber and Prof. Francesco Liistro.One of the highlights of the session was the follow up data of clinical outcomes of the XTOSI Trial. XTOSI (Xtreme Touch Sirolimus coated PTA balloon) is a single arm trial for Sirolimus Coated Balloon investigating the clinical use and safety of the device in the treatment of infrainguinal Peripheral Arterial Disease (PAD). This prospective, premarket, non-randomized, all comers single-arm study, led by PI Prof. Edward Choke enrolled 50 patients to study the Sirolimus Coated Balloon at Sengkang General Hospital, Singapore. It is the world's first trial of Sirolimus Coated Balloon for BTK disease and has the longest follow up data. While the primary endpoints already suggested promising patency and safety at 6 months, the data presented at VEITH 2022 shed more light on the longer-term efficacy and the safety of the Sirolimus Coated Balloon.Prof. Edward Choke, further presented updates on the FUTURE SFA and FUTURE BTK RCTs, a family of randomised trials set to enrol 279 and 219 patients respectively, against standard uncoated balloon in 2:1 fashion and are ongoing in Singapore, Taiwan and Thailand. FUTURE BTK has already completed 25% of its enrolment target, credits to the principal investigators of all sites involved.Sirolimus Coated Balloon for PAD continues its march, knocking on the doors of the US and lighting up the iconic New York Times Square with a dazzling display of the study results of XTOSI and the recruitment status of the FUTURE BTK.Watch the complete session to know more about exciting clinical data:This story is provided by PRNewswire.will not be responsible in any way for the content of this article. (ANI/PRNewswire)( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Pahalgam Terror Attack

Tahawwur Rana

IPL 2025

CM Devendra Fadnavis

Mumbai Local

Weather Update

Sengkang General HospitalFOLLOW

Sengkang general hospital, Latest News

Business :Sirolimus Coated Balloon in BTK Treatment makes a bold presence at VEITH 2022 - Lights up NY Times Square, NASDAQ

VEITH 2022 witnessed a surge of supporting clinical data for Sirolimus Coated Balloon in the treatment of Below-the-Knee (BTK) disease. Concept Medical Inc. hosted a lunch symposium titled 'Sirolimus Coated Balloon in PAD Treatment: Choice of The Fut ...